knowledge -WSS

knowledge

author：Wikipedia 2025-09-29 22:47:45 - browse：57

A view of different flags of the European Union Members. -- first opinion coverage from STAT — Ronald Wittek, Pool Photo via AP

Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices varies widely across Europe, making it more challenging for biopharma companies to efficiently launch products in multiple countries and contributing to the disparities in access across the continent.

But change is on the horizon: In less than 15 months, the European Union will establish and begin to implement a standardized, pan-EU framework, which all 27 of member states will be required to use to assess the clinical evidence of newly submitted products or devices. A key pillar of the EU’s Regulation on Health Technology Assessment (HTA), the Joint Clinical Assessment (JCA) aims to establish a single, transparent process to reduce redundant practices and bring life science innovation faster to patients in Europe — no matter where they live.

In a longstanding problem in Europe, access to — and the availability of — medication varies across the member states. For example, in Germany, 87% of products approved by the European Medicines Agency (EMA) have full availability (the product gained access on the public reimbursement list without any restrictions to the patient population). In Poland, that figure drops to 8%, according to a report published by the European Federation of Pharmaceutical Industries. Meanwhile, there is a tremendous difference in the gap between an oncology therapy receiving marketing authorization and a formal positive reimbursement decision, ranging from an average of 86 days in Denmark to 981 days in Latvia.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Personalized medicine goes far beyond genetics

focus

WSS

Scrutiny of post

Study finds gene variants tied to breast cancer risk in Black women

Biotech startup Celsius cuts 75% of staff ahead of first trial start

Fentanyl is making it harder to start addiction treatment

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

ASCO eve: Let’s set the table for this year's meeting

knowledge

knowledge

explore

Continuity nursing helped my family in our darkest PICU moments

Personalized medicine goes far beyond genetics

Affirmative action in medical school literally saved lives

Pharma showers House GOP doctor with campaign cash

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Group behind ProMed defends move to subscription

Novavax promises a turnaround & Lilly roils the obesity market

A controversial new treatment promises to make little people taller

Wildfire smoke exposes gaps in outdoor worker protections

2 officers injured in shooting in Orlando, police say

knowledge

Scrutiny of post

2 officers injured in shooting in Orlando, police say

Pharma showers House GOP doctor with campaign cash

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

As a primary care physician, here's how I hope to partner with AI

2 officers injured in shooting in Orlando, police say

focus

knowledge

focus

hotspot